Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes

Takashi Ito, Koko Asakura, Katsuhiko Tougou, Tsuyoshi Fukuda, Ryuji Kubota, Shinpei Nonen, Yasushi Fujio, Junichi Azuma

Department of Clinical Pharmacology and Pharmacogenomics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan
Running title: Regulation of CYP2E1 under hypertonic environments

Address correspondence to: Junichi Azuma, Department of Clinical Pharmacology and Pharmacogenomics, Graduate School of Pharmaceutical Sciences, Osaka University. 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. Tel. +81-6-6879-8258; Fax. +81-6-6879-8259; E-mail: azuma@phs.osaka-u.ac.jp

List of abbreviations: CYP; cytochrome P450, UGT; UDP-glucuronosyltransferase, TonE; tonicity-response element, TonEBP; tonicity-response element binding protein, TauT; taurine transporter, GAPDH; glyceraldehydes-3-phosphate hydrogenase, RT-PCR; reverse transcription-polymerase chain reaction, EMSA; electrophoretic mobility shift assay, Suc; sucrose
Abstract

Whereas the liver as well as the other organs is continually exposed to the change of osmotic status, it has never been investigated whether activities and gene expressions of drug-metabolizing enzymes, including cytochromes P450, are controlled dependent on osmotic change in the liver. In the present study, we identified that CYP2E1 is induced under hypertonic environments at a transcriptional level in human primary hepatocytes, as assessed by cDNA microarray and real time-RT-PCR analyses. Consistently, both a protein level and the catalytic activity of CYP2E1 were increased in response to hypertonic condition. In promoter-reporter assay, it was demonstrated that -586 to -566 in the CYP2E1 5′-flanking region was necessary for 2E1 promoter activation by hypertonic stimulation. Importantly, tonicity-response element (TonE) consensus sequence was found at -578 to -568 in human CYP2E1 5′-flanking region, and electrophoretic mobility shift assay demonstrated the interaction of TonE binding protein (TonEBP) with TonE motif of CYP2E1 promoter. Furthermore, co-transfection of a CYP2E1 promoter construct with wild-type TonEBP expression vector enhanced promoter activity under both isotonic and hypertonic conditions, whereas dominant-negative TonEBP suppressed an induction of CYP2E1 promoter activity. These results indicate that the level of CYP2E1 is induced by hypertonic condition via TonEBP transactivation. The present study suggests that osmotic status may influence individual responses to the substrate of CYP2E1.
Introduction

The liver is a main organ to metabolize and detoxify the xenobiotics such as pharmaceutical drugs and chemical toxicants, and abounds in drug-metabolizing enzymes, including Cytochromes P450 (P450s) superfamily proteins (Gonzalez, 1988; Gonzalez, 2005). Among P450 superfamily CYP1, CYP2 and CYP3 families especially play an important role in metabolism of xenobiotics. It is well known that the genes of these enzymes are regulated by xenobiotics, hormones, and pathological conditions (Gonzalez, 1988), leading to change the catalytic capacity of drug-metabolism. Whereas the mechanisms of chemical-induced transcriptional activation of P450 genes have been revealed, that of CYP2E1 is complex and not well understood. In addition to the regulation by xenobiotics, the level of CYP2E1 is influenced by pathophysiological conditions, e.g., CYP2E1 expression is induced under obesity, diabetes, alcoholic and non-alcoholic steatohepatitis (Caro and Cederbaum, 2004). Further, the increased CYP2E1 level was also observed even in physiological status, such as in overfed rats (Raucy et al., 1991), in rats fed high fat diet (Yoo et al., 1991), and in fasted rats (Hong et al., 1987; Johansson et al., 1988). Although several reports demonstrated that hormones, such as insulin (De Waziers et al., 1995), leptin (Leclercq et al., 2000), thyroid (Peng and Coon, 1998) and growth hormones (Chen et al., 1999), could mediate the regulation of CYP2E1 expression, the molecular mechanisms governing the CYP2E1 expression have remained to be elucidated.

On the other hand, cellular osmolality can be changed by various physiological or pathophysiological conditions, such as food or water intake, nutrition state, various hormones and oxidative stress (Haussinger et al., 1993), suggesting the possibility that the activity of P450s may be influenced by osmotic conditions. Osmotic change in the tissues leads to disturbance of normal ion movement and cell swelling, resulting in cell injury and death (Dmitrieva et al., 2001). In addition, hypertonic stress activates some signaling pathways
associated with the impairment of cell viability, such as c-Jun N-terminal kinase and CD95/epidermal growth factor receptor pathways (Reinehr et al., 2002; Reinehr et al., 2003). On the other hand, it activates the signaling molecules responsible for adapting against hypertonic environment, such as transcriptional factor TonEBP (tonicity-response element binding protein), also called NFAT5, which belongs to Rel/NFkB/NFAT family (Woo et al., 2002a; Ho, 2006). TonEBP is activated under hypertonic environment and regulates osmoprotective genes, such as osmolyte transporters, e.g., taurine transporter (TauT) (Ito et al., 2004), sodium/myo-inositol transporter, betaine/GABA transporter-1 (BGT-1) (Burg et al., 1997), and molecular chaperones, e.g., heat shock protein 70 (Hsp70) (Woo et al., 2002b), osmotic stress protein (Osp94) (Kojima et al., 2004), which confer the resistance to cells against hypertonic environments.

In the present study, we first screened the influence of hypertonicity on gene regulation of P450s and the other drug-metabolizing enzymes in human hepatocytes, and found that the mRNA expression of CYP2E1 is induced under hypertonic environments. Further, we demonstrated the molecular mechanism involved in the CYP2E1 upregulation in response to hypertonic stimulation by analyzing promoter function. This paper provides a new aspect that osmotic environment controls the capacity of drug metabolism and chemical detoxification in the liver.
Materials and Methods

Cell culture

Preserved primary human hepatocytes were purchased from Xeno Tech LLC (KA, USA) and Tissue Transformation Technologies (NJ, USA). Cells were seeded at 1-2.5 x10^5 cells/cm^2 on the plates coated by Collagen type-1, and cultured in Lanford medium (Charls River Japan, Japan), for 2 days. Then, cells were exposed to isotonic or hypertonic media. Hypertonic media were prepared by adding 20-50mM sodium chloride (NaCl+20, NaCl+50) or 50-100mM sucrose (Suc50, Suc100) into the medium, as described previously (Ito et al., 2004). To confirm that the experimental results did not depend on the permeability of the reagents, we generated two kinds of hypertonic conditions by using both permeable (sodium chloride) and impermeable agents (sucrose).

Human hepatocarcinoma cell line, HepG2 cells, were cultured in minimum essential medium containing 10% fetal bovine serum (FBS), and then were exposed to hypertonic stress for 24 h, as described above.

Human embryonic kidney cell line, HEK293 cells, were cultured in Dulbecco’s modified Eagle’s medium containing 10% FBS. Cells were transfected with the expression plasmids by using FuGene6 according to manufacture’s protocol (Roche), and then were harvested for EMSA analysis.

cDNA microarray for drug-metabolic enzymes

Total RNA was prepared from cells using QIAzol, according to the manufacture’s instructions (QIAGEN). Total RNA (10 µg) were reverse-transcribed in the presence of SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA), Cy3-dUTP (GE Healthcare BioSciences, NJ, USA), oligo(dT)12-18 primer (Invitrogen), and RNase Inhibitor (Toyobo, Japan) in buffer consisting of 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT and
dNTPs. Reactions were each carried out at 42°C for 80 min, with an addition of SuperScript II Reverse Transcriptase after 40 min from started. The resulting Cy3-labelled cDNA probes were purified with MinElute™ PCR Purification Kit (Qiagen, Germany) according to the manufacturer’s protocol.

Kurabo Multiple Assay DNA array for Human (MAFH-01, Kurabo) were used in gene expression screening. The microarray slides were first pretreated with blocking solution consisting of 4x standard saline citrate (SSC), 0.5% sodium dodecyl sulfate (SDS) and 1% bovine serum albumin (BSA) at 42°C for 45 min. The labeled cDNA in hybridization buffer consisting of 2x SSC, 4x Deahardt’s solution (Sigma-Aldrich, MO, USA), salmon sperm DNA (Invitrogen) were denatured at 95°C for 2 min and cooled to room temperature (RT). Then, cDNA were applied to each individual array window and hybridized at 65°C for 16 h. After hybridization, the solutions of labeled cDNA on the microarray slide were flushed away by a solution containing 2x SSC and 0.1% SDS, and then the microarray slide was immediately washed in following solutions; 2x SSC and 0.1% SDS at RT for 5 min, 0.2x SSC and 0.1% SDS at RT for 5 min, 0.2x SSC and 0.1% SDS at 55°C for 5 min, 0.2x SSC at RT in a moment and 0.05X SSC at RT for 2 min.

The images for the hybridized array was captured by GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA), and quantified by using the Genepix Pro 6.0 software (Molecular Devices). The adjusted intensity equals the intensity of each gene minus the background value. The genes with an adjusted intensity less than twofold the background value were not detected. The normalized intensity to GAPDH gene were calculated by the following formula and compared with other treatment.

\[
\text{Normalized intensity} = \frac{(X-Z)}{(Y-Z)} \times 10000 \\
\text{X; the adjusted intensity of target gene, Y; the adjusted intensity of GAPDH gene, Z; the median of adjusted intensities of the negative}
\]
controls)

**Real time-quantitative RT-PCR (qRT-PCR)**

Total RNA (1 µg) was subjected to the reverse transcription with Rever Tra Ace (Toyobo), using oligo(dT)_{12-18} primer (Invitrogen) at 42°C for 60 min, followed by PCR. Quantitative RT-PCR analyses were performed by using ABI7700 (Applied Biosystems) with SYBR green and Taq-Gold DNA polymerase (Applied Biosystems). The PCR primers used were shown in Table 1. PCR parameters were as follows: initial denaturation at 95 °C for 5 min to activate Tag DNA polymerase followed by 40 cycles of 15 sec at 95 °C, 1 min at 60 °C. GAPDH was used as an internal control.

**Western blot analyses**

Western blot was performed as previously described (Ito et al., 2004). Anti-CYP2E1 (Calbiochem) and anti-GAPDH antibody (Chemicon, CA) were used.

**Measurement of CYP2E1 activity**

CYP2E1 activity was determined according to previous reports (Dicker et al., 1990; Rodriguez-Antona et al., 2002; Thasler et al., 2006). In brief, cultured primary hepatocytes were washed twice, incubated with 0.5mM p-nitrophenol in Krebs-Henseleit buffer containing 200mg/L glucose at 37 °C for 60 min, and then the reaction were terminated by adding trichloroacetic acid to a final concentration of 5% (w/v).  Cells were harvested, centrifuged at 10,000 x g for 10min, and the supernatants were assayed for 4-nitrocatechol by adding 10M NaOH (1:10) and immediately determining the absorbance at 546nm.

**Plasmids**

A DNA fragment of CYP2E1 promoter region positioning from −1361 to +32 was amplified by PCR using human genomic DNA as a template and the PCR primers -1361F and +32R, which is conjugated with HinDIII site (Table 2), and a XhoI/HinDIII-fragment was cloned into
pGL3-basic (Promega, WI), p2E1-1342. Then this fragment was used as the template for the preparation of different lengths of CYP2E1 promoter region. Primer sequences are shown in Table 2. Different lengths of TauT promoter region from positions −586 to +32 and −566 to +32 were prepared by PCR and inserted into firefly luciferase plasmids pGL3-basic, p2E1-586, p2E1-566. Reporter plasmid containing -230 to +32, p2E1-230 was generated by self-ligation of the NheI-cut fragment of p2E1-586. Mutation of the TonE (tonicity-responsive element) site was generated in p2E1-586 by PCR using the primer -586mutF shown in Table 2. This PCR product was inserted into pGL3 to create p2E1-586mut. The plasmids were verified by sequencing. The reporter plasmid p4x2E1TonE-SV40-Luc was generated by insertion of four copies of the double-stranded TonE motif of CYP2E1 promoter region, 5'-CTAGCGGATC CCATGGAAATT TTCCAGTTCA TGGAAATTTTTTGGAAATTTTCCAG TGGAAATTTTTTCCAG TT-3' into the multi-cloning site pGL3-promoter vector containing SV40 promoter (Promega). The expression vectors carrying TonEBP (pCMV-TonEBP) and dominant-negative TonEBP (pCMV-dnTonEBP) were generated previously (Ko et al., 2000; Ito et al., 2004).

Luciferase assay

Transient transfection into HepG2 cells was performed by using transfection regent Fugene 6 transfection reagent (Roche, Schweiz) according to manufacture’s protocol. Assay was performed by using Dual Luciferase assay system (Promega, WI) as described previously (Ito et al., 2004). Control plasmid, pRL-TK, was cotransfected for used as an internal standard.

Immunofluorescence microscopic examination

Immunofluorescence microscopic examination was performed as described previously (Ito et al., 2007). Immunostaining was performed using anti-TonEBP(1439-1455) antibody (1:100, Oncogene) and Alexa Fluor 488 secondary antibody (Molecular Probes, CA). Cells were examined by Olympus IX70 (Olympus, Japan).
Electrophoretic mobility shift assay (EMSA)

Nuclear extracts were prepared from HEK293 or HepG2 cells, and EMSA was performed as described previously (Ito et al., 2007). To prepare DNA probes for EMSA, single-strand oligonucleotides (2E1-TonE sense: AACTGGAAAATTCCATG, antisense: CATGGAATTTTCCAGTT) were end-labeled by $\gamma^{32P}$-ATP, and then were annealed at room temperature. Nuclear extracts were incubated with $^{32P}$-labeled DNA probe (10nM) and poly dI-dC at 30 ºC for 20 min. To perform the competition assay, excess concentration (500nM) of wild or mutant 2E1-TonE, wild TauT-TonE oligonucleotides (2E1-TonEmut sense: AACTCGATCATTCATCCATG, antisense: CATGGAATGATCGAGTT, TauT-TonE sense: AGCTGGTATTTTCCACCCAG, antisense: CTGGGTGGAAAAATACCAGCT) (Ito et al., 2007) was preincubated for 5 min, followed by the incubation with radiolabelled probe. For supershift assay, 2 µg of antibodies (anti-TonEBP (NFAT5) antibody (Oncogene) or control IgG (SantaCruz)) was added after 20 min from adding radiolabelled oligo-probe. The DNA-protein complex was fractioned by 4 % polyacrylamide gel. The gels were dried and processed for autoradiography.

Statistical analysis

Each value was expressed as the mean ± standard error (SE). Statistical significance was determined by Student's t-test. Differences were considered statistically significant when the calculated P value was less than 0.05.
Results

The effects of hypertonic environment on the expressions of drug metabolism-related genes in human hepatocytes

To identify the drug metabolism-related genes regulated by hypertonic stimulation, preliminary DNA microarray analysis was carried out using RNA prepared from two lines of human primary hepatocytes cultured under isotonic or hypertonic media prepared by adding NaCl or sucrose. Based on the analysis, CYP2E1, CYP1A1 and UGT2B4 were upregulated more than 2-fold by treatment with both NaCl and sucrose in both lines of hepatocytes, whereas CYP1A2 was downregulated less than 0.5-fold (Table 3). These results indicate that these genes were regulated by hypertonic stimulation but not the unique influences of NaCl or sucrose. No other drug metabolism-related genes including P450s, UGTs, SLUTs, NATs and GSTs filled the criteria (: more than 2-fold or less than 0.5-fold by treatment with both NaCl and sucrose in both lines of cells).

Quantitative RT-PCR validated the change of each gene in primary hepatocytes exposed to hypertonic conditions (Fig. 1A). In addition, TauT mRNA that has been reported to be induced by hypertonicity in many type of cells (Uchida et al., 1992; Satsu et al., 1999; Ito et al., 2004) was also upregulated in primary hepatocytes exposed to hypertonic conditions, also supporting that the upregulations of CYP2E1, CYP1A1 and UGT2B4 depend on osmotic changes. Further, to confirm the effect of hypertonic stimulation to the other P450s, the levels of CYP2B6, 2C9, 2D6 and 3A4 mRNA were quantified by qRT-PCR. Whereas the expression level of CYP2D6 mRNA was also significantly reduced by treatment with both NaCl and sucrose, CYP2B6 was decreased by sucrose but not NaCl (Fig. 1B). Additionally, the levels of CYP2C9 and 3A4 were not changed.
CYP2E1 is upregulated and activated under hypertonic conditions in human primary hepatocytes

To clarify the effect of hypertonic stimulation on CYP2E1 expression, temporal changes of CYP2E1 mRNA was measured (Fig. 2A). The level of CYP2E1 mRNA was upregulated after 24-48h, but not 3 or 8h, of the exposure to hypertonic condition. Further, we investigated the effect of hypertonic stresses on CYP2E1 protein level by western blot analyses and catalytic activity of p-nitrophenol as CYP2E1 activity. Consistent with the mRNA level, CYP2E1 protein was also induced in cells exposed to hypertonic conditions for 24-48h (Fig. 2B). Concomitantly, CYP2E1 activity was increased by the exposure of hepatocytes to hypertonic conditions for 24-48 h (Fig. 2C).

Identification of tonicity response element in promoter region upstream of human CYP2E1 gene

It is well known that the level of CYP2E1 as well as the other P450s in HepG2 cell line is very low (Thasler et al., 2006), but is detectable at mRNA level (Sumida et al., 2000). We also ascertained that the ratio of CYP2E1 mRNA to GAPDH mRNA in HepG2 cells was less than 1,000 times compared with that in primary hepatocytes (Data not shown). However, the upregulation of CYP2E1 mRNA in response to hypertonic environments was observed in HepG2 cells (Fig. 3A), indicating that HepG2 cells conserve the signaling pathways governing the CYP2E1 upregulation in response to hypertonic stimulations. Thus, HepG2 cells are available to analyze the molecular mechanisms for hypertonicity-induced CYP2E1 upregulation. Additionally, consistent with the data from primary hepatocytes, the increases of CYP1A1 and UGT2B4 and the decrease of CYP1A2 mRNA were also observed in HepG2 cells (Data not shown).
To determine the promoter region regulating the CYP2E1 expression under hypertonic stimulation, promoter gene assay was performed by using promoter-reporter plasmids containing different lengths of promoter region (Fig. 3B). Hypertonic stimulations activated promoter activity in cells transfected with p2E1-1342 or p2E1-586, but not p2E1-566 or p2E1-230. Thus, promoter sequence from -586 to -566 was necessary for the promoter activation by hypertonic stimulations. Importantly, we identified tonicity response element (TonE) motif (TGGAAANNC/TNC/T) in the CYP2E1 promoter region in human genome sequence (NCBI ID: NT_017795) (Fig. 3C: underlined sequences). As expected, mutagenesis at this motif (p2E1-586mut) eliminated the promoter activation induced by hypertonic stimulations (Fig. 3C).

Further, promoter activity driven on reporter plasmid containing four repeat of TonE motif (p4x2E1TonE-SV40) was activated by hypertonicity, whereas that driven on no TonE motif-containing reporter plasmid was not (Fig. 4). These results indicate that this TonE-consensus motif is crucial for regulation of 2E1 promoter activity in response to hypertonicity.

**Regulation of CYP2E1 promoter activity by TonEBP**

It is well established that activated TonEBP is translocated into nucleus under hypertonic condition in many types of mammalian cells (Ko BC et al, 2000; Lopez-Rodriguez et al., 2001). Nuclear translocation of TonEBP was also ascertained in HepG2 cells cultured in hypertonic media for 24 hours (Fig. 5A). We investigated whether TonE locating in 2E1 promoter region interacts with TonEBP protein. In nuclear extract from HEK 293 cells transfected with expression vector carrying TonEBP, protein-DNA complex was detected, as assessed by EMSA (Fig. 5B). This complex was competed by unlabelled probe or unlabelled TauT-TonE.
oligonucleotides which correspond to the TonEBP consensus sequence in the *TauT* gene promoter but not by unlabelled oligonucleotides with the consensus sequence mutated. Further, DNA-protein complex formation was shifted by anti-TonEBP antibody but not control IgG, indicating that this DNA-protein complex consists of TonEBP. Consistently, DNA-TonEBP complex was also detected in nuclear extracts obtained from HepG2 cells and this complex was increased by hypertonic stimulation, as assessed by EMSA (Fig. 5C), indicating that hypertonic stimulations enhance TonEBP transactivation and binding to TonE motif in CYP2E1 promoter.

Next, we confirmed whether TonEBP regulated CYP2E1 promoter activity through TonE motif. Luciferase activity driven on TonE-containing promoter-reporter plasmids (p2E1-1342, p2E1-586), but not mutated plasmid (p2E1-586mut), was increased by co-transfection of TonEBP-expressing vector even in isotonic condition (Fig. 6A,B). TonEBP overexpression resulted in enhancement of hypertonicity-induced activation of CYP2E1 promoter. Furthermore, promoter activation driven on p2E1-1342 were suppressed by co-transfection of expression vector carrying dnTonEBP both in isotonic and in hypertonic conditions (Fig. 6A). Thus, TonEBP is a crucial regulator of basal and hypertonicity-induced expression of CYP2E1.
Discussion

Activities and expressions of P450s are altered under wide variety of conditions, such as nutrition intake, fasting, and pathophysiological conditions. In the present study, we investigated the hypothesis that drug-metabolizing enzymes were regulated under hypertonic environments, and demonstrated the upregulation of CYP2E1, CYP1A1 and UGT2B4 and the downregulation of CYP1A2 and CYP2D6 in response to hypertonic conditions in human hepatocytes. Further, we demonstrated that TonEBP is involved in hypertonicity-induced CYP2E1 upregulation through TonE motif of its promoter region. Our results are the first demonstration that physiological osmotic state controls the activity and expression of drug-metabolizing enzymes.

Previous reports show that there are some putative transcriptional factor-binding motifs, such as STAT, AP-1, NFAT, NFkB, C/EBP, at -671 to -544 of CYP2E1 5’-flanking region (Abdel-Razzak et al., 2004), while TonE motif is found at -578 to -568. Our results presented here revealed that this region is necessary for hypertonicity-induced activation of CYP2E1 promoter. Because putative binding sequences of other NFAT family proteins and NFkappaB are overlapped with TonE at -578 to -568, not only TonEBP but also other NFAT family proteins and NFkappaB were predicted to be involved in the regulation of CYP2E1 promoter in response to hypertonicity. However, it has been demonstrated that other NFATs and NFkappaB are not activated by hypertonic stimulation, while TonEBP is activated (Lopez-Rodriguez et al., 2001). Although TonEBP (NFAT5) is a member of NFAT family proteins, only TonEBP is distinct from other NFATs (NFAT1-4) because it has no calcineulin-regulated domains and is not regulated by Ca+/calcineulin pathway, suggesting its particular function (Ho, 2003). Thus, it makes no sense that either NFAT1-4 or NFkappaB are involved in the upregulation of CYP2E1 in response to hypertonic condition. Consistently, we demonstrated that dnTonEBP overexpression suppressed hypertonicity-induced activation of CYP2E1 promoter. It has been
reported that this deletion mutant does not influence the transcriptional activity of the other NFAT, NF-kappaB in spite of interfering TonEBP dimerization (Lopez-Rodriguez et al., 1999; Trama et al., 2002), indicating that the regulation of CYP2E1 promoter under hypertonic environment is associated with TonEBP transactivation.

In the present study, whereas the reporter activity driven on p4x2E1TonE-SV40 which contains four repeats of TonE motif increases only 2 to 2.5-fold in response to hypertonicity, the 2E1-586 construct, which contains only one of the TonEBP sites, showed over 4-fold increased activities. These results suggest that other promoter regions of CYP2E1, in addition to TonE motif, may be necessary for full activation of CYP2E1 transcription in response to hypertonic stress. Although molecular mechanisms of TonEBP transactivation remain to be elucidated, recent study demonstrated that TonEBP interacts with some proteins, including Hsp90 and PARP-1 (poly(ADP-ribose) polymerase-1), and these proteins modulate TonEBP activity (Chen et al., 2007), indicating that TonEBP function is regulated by interaction with some proteins. Thus, there may be some proteins interacting with TonEBP which bind to DNA in the 5′-flanking region of CYP2E1 and cooperate TonEBP transactivation.

CYP2E1 catalyzes the metabolism of a wide range of exogenous and endogenous low-molecular-weight toxicants, such as alcohol, acetaminophen and lipids (Caro and Cederbaum, 2004). CYP2E1 as well as the other P450 family proteins is critical for body’s defense against xenobiotics exposure. This study demonstrated CYP2E1 is involved in adaptive response against hypertonic environment via TonEBP activation. Although an essential role of TonEBP is not well understood, a number of evidences support that TonEBP plays cytoprotective roles against hypertonic stimulation in mammalian tissues. For example, inhibition of TonEBP by dominant-negative TonEBP resulted in the impairment of cell viability and the increase in the susceptibility against hypertonic stress (Trama et al., 2002; Wang et al.,
2005; Ito et al., 2006). The present study provides a new insight that TonEBP regulates the metabolism of pharmaceutical drugs and exogenous toxicants in the liver. On the other hand, previous reports illustrated that the oxidative stress caused by CYP2E1 is likely to be involved in hepatic pathogenesis, such as alcohol- or acetaminophen-induced hepatic toxicity (Lee et al., 1996; Zaher et al., 1998; Cederbaum et al., 2001; Caro and Cederbaum, 2004; Gonzalez, 2005), implying that TonEBP might contribute to hepatic pathogenesis through CYP2E1 upregulation.

Our investigation revealed novel evidences that CYP1A1 and UGT2B4 are also upregulated by hypertonic stimulations in human hepatocytes. The motif-search analyses failed to detect any TonE consensus sequences within 5 k base pair of 5’-flanking region of each gene in human genome sequence (CYP1A1: NT_010194, UGT2B4: NT_077444). Because the genome structures of drug-metabolizing enzymes, including CYP and UGT superfamilies, are commonly complex, the regulation of these genes may be involved with cis-elements far from each transcript start site, or controlled by other TonEBP-independent pathway.

In addition, we identified the reduction of CYP1A2 and CYP2D6 mRNAs in response to hypertonic environments. Although the regulatory mechanisms of the transcription of these enzymes are well investigated, we cannot found any putative transcript factors involved in the downregulation of CYP1A2 and CYP2D6 by hypertonic stress. On the other hands, hypertonic stress has been reported to enhance mRNA decay (Teixeira et al., 2005). Thus, it is also possible that mRNA decay pathway may target these genes, leading to lower the stability of these mRNAs. Furthermore, CYP2B6 mRNA was downregulated by the exposure to sucrose, but not NaCl, indicating that the induction of CYP2B6 is independent on the effect of hypertonic stress. Since these P450s are responsible for the metabolism of a large number of drugs and changes and may have clinical consequences, further studies will be required to clarify the molecular mechanism and the clinical significance of these findings.
In the present study, we performed cDNA microarray for only 2 lines (lots) of primary hepatocytes. Based on the results obtained from DNA microarray, the levels of no other genes were altered by hypertonicity among P450, UGT, NAT and SULT families. As it is well known that the expression levels of these genes are widely different between individuals, the data of each gene widely differ between different lines of hepatocytes. Furthermore, we could not determine the change of the genes expressed at low level because of the scattered data and/or the limitation of detection. Taken together, it is hardly concluded that we detected all of genes susceptible for hypertonic environments by using microarray. Indeed, further experiments by qRT-PCR analysis have identified the reduction of CYP2B6 and CYP2D6 mRNAs in spite of undetectable by DNA microarray technique.

In summary, we demonstrated that the level of CYP2E1 is upregulated under the hypertonic condition via TonEBP transactivation. Because tissue and plasma osmolality is altered even by common events in human life, such as nutrients, hormones and dehydration (Haussinger et al., 1993), metabolizing capacity of CYP2E1 is likely to be changed in daily life. Additionally, pathophysiological changes of osmolality may affect to the activity and expression of CYP2E1 in the liver; e.g., the upregulation of CYP2E1 in diabetes could be associated with an increase in osmolality caused by acidosis (Owens et al., 1998). This unique response of CYP2E1 to hypertonicity may contribute to the wide variety of individual responses to drug therapy, and further studies will be required to determine the clinical importance of TonEBP/CYP2E1 pathway in drug metabolism.

Acknowledgements— We are deeply grateful to Dr. Isao Miyakawa (Kurabo, Japan) for his help.
We thank Ms. Yasuko Murao for her excellent secretary works.


Woo SK, Lee SD, Na KY, Park WK and Kwon HM (2002b) TonEBP/NFAT5 stimulates


MOL: 33480

FOOT NOTE

Financial Support:

This study was supported in part by a Grants-in-Aid from the Ministry of Health, Labour and Welfare and from the Ministry of Education, Science, Sports and Culture of Japan. This study was also partly granted by Taisho Pharmaceutical Ltd, Takeda Science Foundation, The Salt Science Research Foundation (No.0722) and The Nakatomi Foundation.
Figure legends

Fig. 1  Regulation of drug-metabolizing enzymes in human primary hepatocyte culture.
Real-time RT-PCR was carried out by using specific primers, shown in Table 1, with total RNA prepared from human primary hepatocytes cultured in isotonic (Iso) or hypertonic media (NaCl +50 mM; N50, or 100 mM; S100) for 24 h. Data were shown in bar graphs and represent the mean ± SE, n=5. Data were obtained from five independent lines of primary hepatocytes. *; p<0.05, **; p<0.01 v.s. isotonic condition.

Fig. 2  Induction of CYP2E1 at mRNA and protein level under hypertonic conditions in human primary hepatocyte culture.  (A) Real time RT-PCR, (B) Western blot were carried out to determine the level of CYP2E1 mRNA and protein of human primary hepatocytes cultured in hypertonic medium (NaCl +50 mM; N50) for indicated time. (C, D) CYP2E1 activity of human primary hepatocytes cultured in isotonic or hypertonic media (NaCl +50 mM; N50, or sucrose 100 mM; S100) for indicated time were measured by using p-nitrophenol as CYP2E1 substrate. Data represent the mean ± SE, n=3. *; p<0.05, **; p<0.01 v.s. isotonic condition. Similar results were obtained from at least two independent cell preparations.

Fig. 3  5’-flanking region necessary for transcriptional activation of CYP2E1 gene by hypertonic stimulation.  (A) Quantitative RT-PCR was carried out with total RNA prepared from HepG2 cells cultured in isotonic (I) or hypertonic media (NaCl +50mM; N50, Sucrose 100mM; S100) for 24 h. Data obtained from three independent cell preparations were shown in bar graphs and represent the mean ± SE, n=3. (B-C) Luciferase assay driven on CYP2E1 promoter-reporter constructs ((B) p2E1-1342, p2E1-586, p2E1-566 or p2E1-230; (C) p2E1-586 or p-586mut). HepG2 cells were co-transfected with each promoter-reporter construct.
and pRL-TK, and cultured in isotonic or hypertonic media for 24 h. Then, luciferase activities were measured. Underlines indicate consensus sequence of TonE. Data are shown as fold of corresponding control cells cultured in isotonic medium and represent the mean ± SE, n=4. *; p<0.05, **; p<0.01 v.s. isotonic condition. Each experiment was repeated at least three times with independent cell preparations.

Fig. 4 Identification of tonicity response element (TonE) in CYP2E1 promoter. Promoter constructs, p4x2E1TonE-SV40 or empty pGL3-SV40, were co-transfected with pRL-TK into HepG2 cells, and cultured in isotonic (Iso) or hypertonic media (NaCl +50 mM; N50, Sucrose 100 mM; S100) for 24 h. Then, luciferase activities were measured. Data are shown as fold of corresponding control cells cultured in isotonic medium and represent the mean ± SE, n=3. *; p<0.05, **; p<0.01 v.s. isotonic condition. Each experiment was repeated at least three times with independent cell preparations.

Fig. 5 TonEBP binds with TonE motif in CYP2E1 promoter. (A) HepG2 cells were exposed to hypertonic conditions for 24 h and were then assessed by immunocytochemistry using anti-TonEBP antibody. (B, C) EMSA was performed with nuclear extract from HEK293 cells transfected with pFLAG-TonEBP (B) or HepG2 cells cultured in isotonic (I) or hypertonic (Suc100) (H) media (C) and 32P-labeled 2E1-TonE oligonucleotide. w: wild-type oligonucleotide, T: TonE motif encoded in 5'-flanking region of TauT gene (Ito et al., 2004), mu: mutant oligonucleotide,. Arrows and arrowheads indicate TonEBP/DNA complex and super shifted bands, respectively.

Fig. 6 Involvement of TonEBP on hypertonicity-induced activation of CYP2E1 promoter.
Effect of expression vector carrying wild type or dominant-negative TonEBP on promoter activity driven on CYP2E1 promoter-reporter constructs. (A) HepG2 cells were co-transfected with p2E1-1342 and pRL-TK and each expression vector (pcDNA(100 ng/well), pCMV-TonEBP (1 ng/well) and pCMV-dnTonEBP(100 ng/well)) and cultured in isotonic (White bar) or hypertonic media (NaCl +50 mM; light gray bar, Sucrose 100 mM; dark gray bar) for 24 h. (B) HepG2 cells were transfected with reporter plasmids (p2E1-586 or p2E1-586mut) and expression vectors (pcDNA (100 ng/well); white bar or pCMV-TonEBP (100 ng/well); black bar), and cultured in isotonic medium for 24 h. Then, luciferase activities were measured. Data are shown as fold of corresponding control cells cultured in isotonic medium and represent the mean ± SE, n=4. *; p<0.05, **; p<0.01 v.s. isotonic condition, ###; p<0.01 v.s. pcDNA. Each experiment was repeated three times with independent cell preparations.
Table 1  PCR primers and conditions used in RT-PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>primer sequence</th>
<th>Tm anealing</th>
<th>amplicon size</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>forward: 5'-GATCCTTTGTGATCCAGGCTC-3'</td>
<td>60 ºC</td>
<td>122 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-GAAACTCCGTGGGCGACAT-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP1A2</td>
<td>forward: 5'-CTTTGACAAGAAACAGTTGTCG-3'</td>
<td>60 ºC</td>
<td>226 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-AGTGTCAGCTCCTCTGTTGACAT-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2B6</td>
<td>forward: 5'-GGCCATACGGAGGCCCTTG-3'</td>
<td>60 ºC</td>
<td>236 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-AGGGCCCCCTTTGGATTTCCG-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2C9</td>
<td>forward: 5'-ACATTGACCTTCTCCCACCAGGC-3'</td>
<td>62 ºC</td>
<td>357 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-CAAATCCATGGACAACTGGAGTG-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2D6</td>
<td>forward: 5'-GGCTGCTGGACCTAGCTCAG-3'</td>
<td>60 ºC</td>
<td>264 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-GGTCTCTCATTGAAGCTCG-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2E1</td>
<td>forward: 5'-TCAATCTCTGGACCCCAACTGT-3'</td>
<td>60 ºC</td>
<td>115 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-AGTCACGGTGATACCAGTCCATT-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A4</td>
<td>forward: 5'-GCAGGAGAAAATTGATGCGATT-3'</td>
<td>60 ºC</td>
<td>76 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-GTCAAGATACTCCATCTGTAGCACAGT-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UGT2B4</td>
<td>forward: 5'-GGCTGTACAGTGATACCCAGCAG-3'</td>
<td>60 ºC</td>
<td>147 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-CATGGCTGTACAGTGATACCCAGCAG-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TauT</td>
<td>forward: 5'-CGCTCTCTTGCCCTTTTTATGATCG-3'</td>
<td>60 ºC</td>
<td>109 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-CATGGGCAATGGGAAAATGGG-3'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>forward: 5'-CAATGGGAAATCCCATCCACATC-3'</td>
<td>60 ºC</td>
<td>101 bp</td>
</tr>
<tr>
<td></td>
<td>reverse: 5'-TGAAGACGCGCAGTGGACCTC-3'</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 2  PCR primers used to generate promoter-reporter constructs

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2E1-1361F</td>
<td>5’-CATCTGTCAGTTCTCACCTC-3’</td>
</tr>
<tr>
<td>2E1-586F</td>
<td>5’-TTCTCGAGTTCTTCCCATGGAATTTCAGTT-3’</td>
</tr>
<tr>
<td>2E1-586mutF</td>
<td>5’-TTCTCGAGTTCTTCCCATGGAATTTCAGTT-3’ GGTAACTTAACTTGAGAAAGTGGA-3’</td>
</tr>
<tr>
<td>2E1-566</td>
<td>5’-TTCTCGAGTTCTTCCCATGGAATTTCAGTT-3’ GGTAACTTAACTTGAGAAAGTGGA-3’</td>
</tr>
<tr>
<td>2E1+32R</td>
<td>5’-TTAAGCTTTGGACACCAGCGGAGGAAG-3’</td>
</tr>
</tbody>
</table>

* Restriction enzyme sites or mutated site are indicated by underlines or lower-case, respectively.
Table 3  Influence of hypertonic stimulation on gene expression of drug-metabolizing enzymes in human primary hepatocytes (cDNA microarray analysis)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Line 1 NaCl+20</th>
<th>NaCl+50</th>
<th>Suc50</th>
<th>Suc100</th>
<th>Line 2 NaCl+20</th>
<th>NaCl+50</th>
<th>Suc50</th>
<th>Suc100</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>1.4</td>
<td>4.3</td>
<td>1.7</td>
<td>3.2</td>
<td>2.5</td>
<td>2.0</td>
<td>3.1</td>
<td>1.3</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>0.3</td>
<td>2.0</td>
<td>0.1</td>
<td>0.9</td>
<td>1.4</td>
<td>0.2</td>
<td>0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>1.3</td>
<td>3.2</td>
<td>0.6</td>
<td>2.4</td>
<td>6.0</td>
<td>6.6</td>
<td>8.5</td>
<td>3.5</td>
</tr>
<tr>
<td>UGT2B4</td>
<td>1.7</td>
<td>2.5</td>
<td>3.3</td>
<td>2.3</td>
<td>1.7</td>
<td>3.0</td>
<td>2.6</td>
<td>2.7</td>
</tr>
</tbody>
</table>

Criteria: Change > 2- or <0.5-fold in response to both NaCl (+20 or +50) and scrose (Suc50 or Suc100) exposure compared with isotonic medium in both lines of primary hepatocyte culture (Line 1 and Line 2).
Figure 1
Figure 2
Figure 3

(A) 

![Graph showing CYP2E1/β-actin (fold of control)]

(B) 

- p2E1-1342
- p2E1-586
- p2E1-566
- p2E1-230

![Bar graph showing fold of control for different conditions](N50 S100)

(C) 

- p2E1-586
- p2E1-586mut

![Sequence with mutation highlighted](GGAATTTTCCA GGAATgctagc)

![Bar graph showing fold of control for different conditions](N50 S100)
Figure 5
Figure 6

(A) co-expression

pcDNA

TonEBP

dnTonEBP

Fold of control

(B)

p2E1-586

p2E1-586mut

Fold of control

Figure 6